Wipro Limited has announced the incorporation of its step-down subsidiary, Wipro Life Science Solutions, LLC, as part of its strategy to explore new business opportunities in the life sciences segment. The new subsidiary will focus on providing post-approval pharmaceutical services, aiming to expand Wipro’s presence in the growing life sciences sector.
This development aligns with Wipro’s diversification efforts, allowing the company to tap into the lucrative pharma services market. The entity was incorporated in the United States on October 10, 2024, and Wipro holds 100% of the shareholding through its subsidiary, Wipro Inc.
Wipro has been making strides in various sectors, and this move marks a significant step towards further strengthening its foothold in the life sciences industry.
